iM Investment Partners
VC Fund
Seoul, South Korea
iM Investment Partners is an investment firm. It is an affiliate of DGB Finance Group.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 8%
Last updated:
For AI agents: llms.txt
Industries iM Investment Partners invests in
Stages iM Investment Partners invests in
Countries iM Investment Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Pharmaceutical 5 (38%)
- Biotechnology 4 (31%)
- Health Care 3 (23%)
- Biopharma 2 (15%)
- Manufacturing 2 (15%)
Stage
- Seed 3 (23%)
- Series A 3 (23%)
- Series B 3 (23%)
- Series C 2 (15%)
- Series D 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Kwon Jun-hee
Founder & CEO
|
Founder & CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Automata
|
Automata creates AI-powered tools like AI agents and smart integrations that simplify how teams plan, communicate, and work. The company solves business problems by enabling AI to build, manage, and evolve software workflows while humans guide the AI to deliver real value.Automata provides industry-tailored AI solutions | $7.1M / Series A / Apr 24, 2026 | |
IVWorks
|
IVWorks has been at the forefront of the compound semiconductor industry .We are clearly recognized as the high-tech innovator of advanced wide bandgap semiconductor epitaxial wafer products and wafer services to the semiconductor industry.IVWorks technology leadership and passion towards the innovation enable the company to provide a uniqueservice that is second to none.The epitaxial wafer products that we manufacture can be used by chip companies to produce the chips which enable a wide range of high-tech applications. The unique properties of these materials enable a diverse range of markets including wireless communications, advanced solar power, high efficiency LED lighting, efficient power switching and a range of consumer and industrial applications using advanced power devices.Beyond this, IVWorks is also working with leading R&D groups and on a number of major government funded programs to develop the next generation of technology which will combine the scale and maturity of the silicon industry with the advanced properties of compound semiconductors. | $3.9M / Venture - Series Unknown / Apr 02, 2026 | |
Anabatic Semiconductor
|
Anabatic Manufacturing of electronic components, computers, video, audio, and communication equipment | $10M / Series B / Mar 25, 2026 | |
Ticaros
|
Ticaros is a biotech company that develops immune anti-cancer drugs. | $14M / Series D / Mar 03, 2026 | |
Partridge Systems
|
Partridge Systems develops an automotive data platform that enables real-time data transfer, sharing, and structured data management. The platform offers end-to-end capabilities, including data collection, storage, and deployment pipelines for processing vehicle big data through web-based visualization tools. It allows users to access streamingdata without local downloads and supports seamless collaboration among engineers worldwide. | $4.3M / Series A / Nov 26, 2025 | |
MediMabBio
|
MediMabBio platform uses systems biology combined with sophisticated immunological solutions to identify significantly improving immuno-oncology drugs that can actively target a range of solid tumors. The antibody discovery I-O platform brings the advantages of rational drug design to large molecule therapeutic development. | $17.8M / Series B / Oct 24, 2025 | |
Lutem Bio
|
Lutem Bio is an online medicine firm that is intended for general health. The company provides medicine for memory, cognition, immunity, gut, joints, and bones, among others, enabling customers to get medicines recommended by a doctor. | $3M / Series A / Oct 17, 2025 | |
Yeoshin
|
Yeoshin is a skin treatment information platform. | $7.2M / Series C / Sep 08, 2025 | |
SCBIO
|
SCBIO is a pharmaceutical company that makes drugs with specialized technologies in immuno-oncology. The company discovers and develops novel therapeutics for future medicine. | $10M / Seed / Sep 01, 2025 | |
DOD
|
DOD is data-driven musical business platform. | $8.5M / Seed / Dec 06, 2024 | |
| See all 13 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does iM Investment Partners invest in?
iM Investment Partners invests primarily in Pharmaceutical, Biotechnology and Health Care startups, most often at Seed and Series A stage. Most of the 13 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact iM Investment Partners?
Public channels for iM Investment Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at iM Investment Partners?
The team at iM Investment Partners includes Kwon Jun-hee (Founder & CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
